Global phenotypic screening for antimalarials

Chemistry and Biology

Volumn 19, Issue 1, 2012, Pages 116-129

  Guiguemde, W Armand ^a   Shelat, Anang A ^a   Garcia Bustos, Jose F ^b   Diagana, Thierry T ^c   Gamo, Francisco Javier ^d   Guy, R Kiplin ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c Novartis Institute for Tropical Diseases   (Singapore)

^d GLAXOSMITHKLINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOQUINOLINE DERIVATIVE; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMISIN; ARTESUNATE; ATOVAQUONE; CHLOROQUINE; DIHYDROOROTATE DEHYDROGENASE; DOXYCYCLINE; HEMOZOIN; LACTATE DEHYDROGENASE; MEFLOQUINE; PROGUANIL; PYRIMETHAMINE; QUININE; SULFADOXINE; THIOREDOXIN REDUCTASE;

ANTIMALARIAL DRUG RESISTANCE; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MALARIA; NONHUMAN; PHENOTYPE; PLASMODIUM FALCIPARUM; REVIEW;

ANTIMALARIALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE; HUMANS; MALARIA; PLASMODIUM FALCIPARUM;

PLASMODIUM FALCIPARUM;

EID: 84856367163     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2012.01.004     Document Type: Review

References (88)

1. S.H. Adjalley, G.L. Johnston, T. Li, R.T. Eastman, E.H. Ekland, A.G. Eappen, A. Richman, B.K. Sim, M.C. Lee, S.L. Hoffman, and D.A. Fidock Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue Proc. Natl. Acad. Sci. USA 108 2011 E1214 E1223
2. T.K. Allu, and T.I. Oprea Rapid evaluation of synthetic and molecular complexity for in silico chemistry J. Chem. Inf. Model. 45 2005 1237 1243 (Pubitemid 41476007)
3. S.C. Almo, J.B. Bonanno, J.M. Sauder, S. Emtage, T.P. Dilorenzo, V. Malashkevich, S.R. Wasserman, S. Swaminathan, S. Eswaramoorthy, and R. Agarwal Structural genomics of protein phosphatases J. Struct. Funct. Genomics 8 2007 121 140 (Pubitemid 50007113)
4. Anonymous M. Geyer, Antimalarial Drug Combination Therapy 2001 Roll Back Malaria / WHO Geneva
5. N. Bahamontes-Rosa, A. Rodriguez-Alejandre, R. Gonzalez-Del-Rio, J.F. Garcia-Bustos, and A. Mendoza-Losana A new molecular approach for cidal vs static antimalarial determination by quantifying mRNA levels Mol. Biochem. Parasitol. 2011 10.1016/j.molbiopara.2011.11.003 Published online November 17, 2011
6. J. Baldwin, C.H. Michnoff, N.A. Malmquist, J. White, M.G. Roth, P.K. Rathod, and M.A. Phillips High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase J. Biol. Chem. 280 2005 21847 21853 (Pubitemid 40827835)
7. A. Bhardwaj, V. Scaria, G.P. Raghava, A.M. Lynn, N. Chandra, S. Banerjee, M.V. Raghunandanan, V. Pandey, B. Taneja, J. Yadav Open Source Drug Discovery Consortium Open source drug discovery - a new paradigm of collaborative research in tuberculosis drug development Tuberculosis (Edinb.) 91 2011 479 486
8. K. Buchholz, T.A. Burke, K.C. Williamson, R.C. Wiegand, D.F. Wirth, and M. Marti A high-throughput screen targeting malaria transmission stages opens new avenues for drug development J. Infect. Dis. 203 2011 1445 1453
9. K. Buchholz, E.D. Putrianti, S. Rahlfs, R.H. Schirmer, K. Becker, and K. Matuschewski Molecular genetics evidence for the in vivo roles of the two major NADPH-dependent disulfide reductases in the malaria parasite J. Biol. Chem. 285 2010 37388 37395
10. J.N. Burrows, K. Chibale, and T.N. Wells The state of the art in anti-malarial drug discovery and development Curr. Top. Med. Chem. 11 2011 1226 1254
11. F. Calderón, D. Barros, J.M. Bueno, J.M. Coterón, E. Fernández, F.J. Gamo, J.L. Lavandera, M.L. León, S.F.J. Macdonald, and A. Mallo An invitation to open innovation in malaria drug discovery: 47 quality starting points from the TCAMS ACS Med. Chem. Lett. 2 2011 741 746
12. A. Cameron, J. Read, R. Tranter, V.J. Winter, R.B. Sessions, R.L. Brady, L. Vivas, A. Easton, H. Kendrick, and S.L. Croft Identification and activity of a series of azole-based compounds with lactate dehydrogenase-directed anti-malarial activity J. Biol. Chem. 279 2004 31429 31439 (Pubitemid 39037810)
13. C.J. Canfield, M. Pudney, and W.E. Gutteridge Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro Exp. Parasitol. 80 1995 373 381
14. S.R. Choi, A.B. Beeler, A. Pradhan, E.B. Watkins, J.M. Rimoldi, B. Tekwani, and M.A. Avery Generation of oxamic acid libraries: antimalarials and inhibitors of Plasmodium falciparum lactate dehydrogenase J. Comb. Chem. 9 2007 292 300
15. S.R. Choi, A. Pradhan, N.L. Hammond, A.G. Chittiboyina, B.L. Tekwani, and M.A. Avery Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors J. Med. Chem. 50 2007 3841 3850 (Pubitemid 47292047)
16. J.M. Coteron, M. Marco, J. Esquivias, X. Deng, K.L. White, J. White, M. Koltun, F. El Mazouni, S. Kokkonda, and K. Katneni Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential J. Med. Chem. 54 2011 5540 5561
17. G.J. Crowther, A.J. Napuli, J.H. Gilligan, K. Gagaring, R. Borboa, C. Francek, Z. Chen, E.F. Dagostino, J.B. Stockmyer, and Y. Wang Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds Mol. Biochem. Parasitol. 175 2011 21 29
18. L. Dembele, A. Gego, A.M. Zeeman, J.F. Franetich, O. Silvie, A. Rametti, R. Le Grand, N. Dereuddre-Bosquet, R. Sauerwein, and G.J. van Gemert Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery PLoS ONE 6 2011 e18162
19. X. Deng, A. Nagle, T. Wu, T. Sakata, K. Henson, Z. Chen, K. Kuhen, D. Plouffe, E. Winzeler, and F. Adrian Discovery of novel 1H-imidazol-2-yl- pyrimidine-4,6-diamines as potential antimalarials Bioorg. Med. Chem. Lett. 20 2010 4027 4031
20. N.V. Dharia, A. Chatterjee, and E.A. Winzeler Genomics and systems biology in malaria drug discovery Curr. Opin. Investig. Drugs 11 2010 131 138
21. C.A. Diaz, J. Allocco, M.A. Powles, L. Yeung, R.G. Donald, J.W. Anderson, and P.A. Liberator Characterization of Plasmodium falciparum cGMP-dependent protein kinase (PfPKG): antiparasitic activity of a PKG inhibitor Mol. Biochem. Parasitol. 146 2006 78 88 (Pubitemid 43132805)
22. C. Doerig, and L. Meijer Antimalarial drug discovery: targeting protein kinases Expert Opin. Ther. Targets 11 2007 279 290 (Pubitemid 46290953)
23. A.M. Dondorp, F. Nosten, P. Yi, D. Das, A.P. Phyo, J. Tarning, K.M. Lwin, F. Ariey, W. Hanpithakpong, and S.J. Lee Artemisinin resistance in Plasmodium falciparum malaria N. Engl. J. Med. 361 2009 455 467
24. R. Ettari, F. Bova, M. Zappalà, S. Grasso, and N. Micale Falcipain-2 inhibitors Med. Res. Rev. 30 2010 136 167
25. E. Fan, D. Baker, S. Fields, M.H. Gelb, F.S. Buckner, W.C. Van Voorhis, E. Phizicky, M. Dumont, C. Mehlin, and E. Grayhack Structural genomics of pathogenic protozoa: an overview Methods Mol. Biol. 426 2008 497 513
26. G.A. FitzGerald Re-engineering drug discovery and development LDI Issue Brief 17 2011 1 4
27. F.J. Gamo, L.M. Sanz, J. Vidal, C. de Cozar, E. Alvarez, J.L. Lavandera, D.E. Vanderwall, D.V. Green, V. Kumar, and S. Hasan Thousands of chemical starting points for antimalarial lead identification Nature 465 2010 305 310
28. J.F. Garcia-Bustos, and F.J. Gamo Phenotypic screens, chemical genomics, and antimalarial lead discovery PLoS Pathog. 7 2011 e1002156
29. R. Garcia-Serna, and J. Mestres Anticipating drug side effects by comparative pharmacology Expert Opin. Drug Metab. Toxicol. 6 2010 1253 1263
30. R. Garcia-Serna, and J. Mestres Chemical probes for biological systems Drug Discov. Today 16 2011 99 106
31. M.J. Gardner, N. Hall, E. Fung, O. White, M. Berriman, R.W. Hyman, J.M. Carlton, A. Pain, K.E. Nelson, and S. Bowman Genome sequence of the human malaria parasite Plasmodium falciparum Nature 419 2002 498 511
32. S. Gassis, and P.K. Rathod Frequency of drug resistance in Plasmodium falciparum: a nonsynergistic combination of 5-fluoroorotate and atovaquone suppresses in vitro resistance Antimicrob. Agents Chemother. 40 1996 914 919 (Pubitemid 26115224)
33. A. Gaulton, L.J. Bellis, A.P. Bento, J. Chambers, M. Davies, A. Hersey, Y. Light, S. McGlinchey, D. Michalovich, and B. Al-Lazikani ChEMBL: a large-scale bioactivity database for drug discovery Nucl. Acids Res. 40 2012 D1100 D1107 10.1093/nar/gkr777 Published online September 23, 2011
34. C. Granchi, S. Bertini, M. Macchia, and F. Minutolo Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials Curr. Med. Chem. 17 2010 672 697
35. W.A. Guiguemde, A.A. Shelat, D. Bouck, S. Duffy, G.J. Crowther, P.H. Davis, D.C. Smithson, M. Connelly, J. Clark, and F. Zhu Chemical genetics of Plasmodium falciparum Nature 465 2010 311 315
36. W.E. Gutteridge, D. Dave, and W.H. Richards Conversion of dihydroorotate to orotate in parasitic protozoa Biochim. Biophys. Acta 582 1979 390 401
37. D.A. Heerding, G. Chan, W.E. DeWolf, A.P. Fosberry, C.A. Janson, D.D. Jaworski, E. McManus, W.H. Miller, T.D. Moore, and D.J. Payne 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI) Bioorg. Med. Chem. Lett. 11 2001 2061 2065 (Pubitemid 32763001)
38. A.L. Hopkins, and C.R. Groom The druggable genome Nat. Rev. Drug Discov. 1 2002 727 730 (Pubitemid 37361545)
39. E.S. Istvan, N.V. Dharia, S.E. Bopp, I. Gluzman, E.A. Winzeler, and D.E. Goldberg Validation of isoleucine utilization targets in Plasmodium falciparum Proc. Natl. Acad. Sci. USA 108 2011 1627 1632
40. M.P. Joachimiak, C. Chang, P.J. Rosenthal, and F.E. Cohen The impact of whole genome sequence data on drug discovery - a malaria case study Mol. Med. 7 2001 698 710 (Pubitemid 33070984)
41. H. Ke, J.M. Morrisey, S.M. Ganesan, H.J. Painter, M.W. Mather, and A.B. Vaidya Variation among Plasmodium falciparum strains in their reliance on mitochondrial electron transport chain function Eukaryot. Cell 10 2011 1053 1061
42. M.J. Keiser, J.J. Irwin, and B.K. Shoichet The chemical basis of pharmacology Biochemistry 49 2010 10267 10276
43. Y. Landry, and J.P. Gies Drugs and their molecular targets: an updated overview Fundam. Clin. Pharmacol. 22 2008 1 18 (Pubitemid 351171284)
44. M. Lessl, J.S. Bryans, D. Richards, and K. Asadullah Crowd sourcing in drug discovery Nat. Rev. Drug Discov. 10 2011 241 242
45. C. McNamara, and E.A. Winzeler Target identification and validation of novel antimalarials Future Microbiol. 6 2011 693 704
46. S. Meister, D.M. Plouffe, K.L. Kuhen, G.M. Bonamy, T. Wu, S.W. Barnes, S.E. Bopp, R. Borboa, A.T. Bright, and J. Che Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery Science 334 2011 1372 1377
47. S. Mok, M. Imwong, M.J. Mackinnon, J. Sim, R. Ramadoss, P. Yi, M. Mayxay, K. Chotivanich, K.Y. Liong, and B. Russell Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription BMC Genomics 12 2011 391
48. T.G. Nam, C.W. McNamara, S. Bopp, N.V. Dharia, S. Meister, G.M. Bonamy, D.M. Plouffe, N. Kato, S. McCormack, and B. Bursulaya A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor ACS Chem. Biol. 6 2011 1214 1222
49. E.R. Nichols Biometrics: theory, applications, and issues 2011 Nova Science Publishers New York
50. G. Nicola, C.A. Smith, E. Lucumi, M.R. Kuo, L. Karagyozov, D.A. Fidock, J.C. Sacchettini, and R. Abagyan Discovery of novel inhibitors targeting enoyl-acyl carrier protein reductase in Plasmodium falciparum by structure-based virtual screening Biochem. Biophys. Res. Commun. 358 2007 686 691 (Pubitemid 46805154)
51. S. Nwaka, and R.G. Ridley Virtual drug discovery and development for neglected diseases through public-private partnerships Nat. Rev. Drug Discov. 2 2003 919 928 (Pubitemid 37419900)
52. F.O. Okumu, and S.J. Moore Combining indoor residual spraying and insecticide-treated nets for malaria control in Africa: a review of possible outcomes and an outline of suggestions for the future Malar. J. 10 2011 208
53. H.J. Painter, J.M. Morrisey, M.W. Mather, and A.B. Vaidya Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum Nature 446 2007 88 91 (Pubitemid 46348043)
54. J. Penna-Coutinho, W.A. Cortopassi, A.A. Oliveira, T.C. Frana, and A.U. Krettli Antimalarial activity of potential inhibitors of Plasmodium falciparum lactate dehydrogenase enzyme selected by docking studies PLoS ONE 6 2011 e21237
55. R. Perozzo, M. Kuo, A.S. Sidhu, J.T. Valiyaveettil, R. Bittman, W.R. Jacobs Jr., D.A. Fidock, and J.C. Sacchettini Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase J. Biol. Chem. 277 2002 13106 13114 (Pubitemid 34952681)
56. I. Petersen, R. Eastman, and M. Lanzer Drug-resistant malaria: molecular mechanisms and implications for public health FEBS Lett. 585 2011 1551 1562
57. R. Pink, A. Hudson, M.A. Mouris, and M. Bendig Opportunities and challenges in antiparasitic drug discovery Nat. Rev. Drug Discov. 4 2005 727 740 (Pubitemid 43090494)
58. D. Plouffe, A. Brinker, C. McNamara, K. Henson, N. Kato, K. Kuhen, A. Nagle, F. Adrián, J.T. Matzen, and P. Anderson In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen Proc. Natl. Acad. Sci. USA 105 2008 9059 9064
59. P.K. Rathod, T. McErlean, and P.C. Lee Variations in frequencies of drug resistance in Plasmodium falciparum Proc. Natl. Acad. Sci. USA 94 1997 9389 9393 (Pubitemid 27357839)
60. G.M. Robertson, and L.M. Mayr Collaboration versus outsourcing: the need to think outside the box Future Med. Chem. 3 2011 1995 2020
61. P.J. Rosenthal Falcipains and other cysteine proteases of malaria parasites Adv. Exp. Med. Biol. 712 2011 30 48
62. M. Rottmann, C. McNamara, B.K. Yeung, M.C. Lee, B. Zou, B. Russell, P. Seitz, D.M. Plouffe, N.V. Dharia, and J. Tan Spiroindolones, a potent compound class for the treatment of malaria Science 329 2010 1175 1180
63. C.P. Sanchez, A. Dave, W.D. Stein, and M. Lanzer Transporters as mediators of drug resistance in Plasmodium falciparum Int. J. Parasitol. 40 2010 1109 1118
64. L.M. Sanz, M.B. Jiménez-Díaz, B. Crespo, C. De-Cozar, M.J. Almela, I. Angulo-Barturen, P. Castañeda, J. Ibañez, E.P. Fernández, and S. Ferrer Cyclopropyl carboxamides, a chemically novel class of antimalarial agents identified in a phenotypic screen Antimicrob. Agents Chemother. 55 2011 5740 5745
65. S. Saralamba, W. Pan-Ngum, R.J. Maude, S.J. Lee, J. Tarning, N. Lindegrdh, K. Chotivanich, F. Nosten, N.P. Day, and D. Socheat Intrahost modeling of artemisinin resistance in Plasmodium falciparum Proc. Natl. Acad. Sci. USA 108 2011 397 402
66. A. Schuffenhauer, N. Brown, P. Ertl, J.L. Jenkins, P. Selzer, and J. Hamon Clustering and rule-based classifications of chemical structures evaluated in the biological activity space J. Chem. Inf. Model. 47 2007 325 336 (Pubitemid 46615937)
67. A. Schuffenhauer, P. Ertl, S. Roggo, S. Wetzel, M.A. Koch, and H. Waldmann The scaffold tree - visualization of the scaffold universe by hierarchical scaffold classification J. Chem. Inf. Model. 47 2007 47 58 (Pubitemid 46225559)
68. R.J. Schwenk, and T.L. Richie Protective immunity to pre-erythrocytic stage malaria Trends Parasitol. 27 2011 306 314
69. A.A. Shelat, and R.K. Guy Scaffold composition and biological relevance of screening libraries Nat. Chem. Biol. 3 2007 442 446 (Pubitemid 47080378)
70. O. Silvie, E. Rubinstein, J.F. Franetich, M. Prenant, E. Belnoue, L. Rénia, L. Hannoun, W. Eling, S. Levy, C. Boucheix, and D. Mazier Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity Nat. Med. 9 2003 93 96 (Pubitemid 36098266)
71. D.C. Smithson, W. Armand Guiguemde, and R.K. Guy Antimalarials Burger's Medicinal Chemistry and Drug Discovery 2010 John Wiley & Sons, Inc.
72. S. Sridaran, S.K. McClintock, L.M. Syphard, K.M. Herman, J.W. Barnwell, and V. Udhayakumar Anti-folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations Malar. J. 9 2010 247
73. F. Stoll, A.H. Göller, and A. Hillisch Utility of protein structures in overcoming ADMET-related issues of drug-like compounds Drug Discov. Today 16 2011 530 538
74. G.L. Strobel, and J. Arnold Essential eukaryotic core Evolution 58 2004 441 446 (Pubitemid 38370199)
75. N. Surolia, and A. Surolia Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum Nat. Med. 7 2001 167 173 (Pubitemid 32148482)
76. D.C. Swinney, and J. Anthony How were new medicines discovered? Nat. Rev. Drug Discov. 10 2011 507 519
77. A.M. Vaughan, M.T. O'Neill, A.S. Tarun, N. Camargo, T.M. Phuong, A.S. Aly, A.F. Cowman, and S.H. Kappe Type II fatty acid synthesis is essential only for malaria parasite late liver stage development Cell. Microbiol. 11 2009 506 520
78. M. Vedadi, J. Lew, J. Artz, M. Amani, Y. Zhao, A. Dong, G.A. Wasney, M. Gao, T. Hills, and S. Brokx Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms Mol. Biochem. Parasitol. 151 2007 100 110 (Pubitemid 44911074)
79. M.I. Veiga, P.E. Ferreira, L. Jörnhagen, M. Malmberg, A. Kone, B.A. Schmidt, M. Petzold, A. Björkman, F. Nosten, and J.P. Gil Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance PLoS ONE 6 2011 e20212
80. T.N. Wells, P.L. Alonso, and W.E. Gutteridge New medicines to improve control and contribute to the eradication of malaria Nat. Rev. Drug Discov. 8 2009 879 891
81. N.J. White, and W. Pongtavornpinyo The de novo selection of drug-resistant malaria parasites Proc. Biol. Sci. 270 2003 545 554 (Pubitemid 36308233)
82. G.L. Wilson, and M.A. Lill Integrating structure-based and ligand-based approaches for computational drug design Future Med. Chem. 3 2011 735 750
83. World Health Organization (2011). World Malaria Report 2011 (http://www.who.int/malaria/world-malaria-report-2011/en/).
84. T. Wu, A. Nagle, T. Sakata, K. Henson, R. Borboa, Z. Chen, K. Kuhen, D. Plouffe, E. Winzeler, and F. Adrian Cell-based optimization of novel benzamides as potential antimalarial leads Bioorg. Med. Chem. Lett. 19 2009 6970 6974
85. T. Wu, A. Nagle, K. Kuhen, K. Gagaring, R. Borboa, C. Francek, Z. Chen, D. Plouffe, A. Goh, and S.B. Lakshminarayana Imidazolopiperazines: hit to lead optimization of new antimalarial agents J. Med. Chem. 54 2011 5116 5130
86. E. Yeh, and J.L. DeRisi Chemical rescue of malaria parasites lacking an apicoplast defines organelle function in blood-stage Plasmodium falciparum PLoS Biol. 9 2011 e1001138
87. B.K. Yeung, B. Zou, M. Rottmann, S.B. Lakshminarayana, S.H. Ang, S.Y. Leong, J. Tan, J. Wong, S. Keller-Maerki, and C. Fischli Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria J. Med. Chem. 53 2010 5155 5164
88. M. Yu, T.R. Kumar, L.J. Nkrumah, A. Coppi, S. Retzlaff, C.D. Li, B.J. Kelly, P.A. Moura, V. Lakshmanan, and J.S. Freundlich The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites Cell Host Microbe 4 2008 567 578 (Pubitemid 352762958)